On Nov. 24, 2020, Roche announced that the FDA had approved a supplemental New Drug Application for Xofluzaﾮ (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza was the first single-dose influenza medicine approved for post-exposure prophylaxis.